Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

GSVA: gene set variation analysis for microarray and RNA-Seq data

Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440

Molecular signatures database (MSigDB) 3.0

Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

The EMBL-EBI search and sequence analysis tools APIs in 2019

Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A. R. N., Potter, S. C., Finn, R. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz268 · Cited by 4,167

T cell exhaustion

Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448

Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease

Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851

Transforming Growth Factor‐Beta Signaling in Cancer: Therapeutic Implications, Challenges, and Pathways to Progress

Alabi, F. A., Okpalanwaka, I. F., Oyegbesan, A., Okoyeocha, E. O. M., Oladejo, M., & Imodoye, S. O. (2025) · MedComm – Oncology · doi:10.1002/mog2.70027 · Cited by 3

The Single-Cell Level Perspective of the Tumor Microenvironment and Its Remodeling by CAR-T Cells

Gao, S., & Sugimura, R. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_10 · Cited by 3

Cancer-associated fibroblast heterogeneity and its role in reshaping immunotherapy in solid cancers: potential strategies and clinical promise

Zu, P., & Yu, Z. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1761070 · Cited by 2

A Unique Intercellular Feedforward Loop From HK1 to TGF‐β1 Promotes the Progression of Hepatocellular Carcinoma

Chen, Q.-T., Huang, Q., Feng, D., Zhao, W., Zhang, Z., Jiang, Z., Han, M., Chen, S., Zhang, Y., Wu, Q., et al. (2026) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70255 · Cited by 2

Immune Checkpoint-Based Therapies in Colorectal Cancer—Current Approaches and Future Perspectives

Nakielska, K., Plewka, J., & Lenart, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104628 · Cited by 2

Cancer Resistance to Immunotherapy

Khoury, R., Shayya, A., Orm, C. B., Deen, O. Z., & Ghanem, H. (2025) · Immuno · doi:10.3390/immuno5030032 · Cited by 2

Using CAR-NK cells to overcome the host resistance to antibody immunotherapy and immune checkpoint blockade therapy

Hu, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00010-2 · Cited by 2

TGFβ1-specific antibody spurs anti-tumour immunity

Cully, M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00058-4 · Cited by 2

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?

Hida, T., & Yamaguchi, T. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1672 · Cited by 2

Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm

Zhu, H., Zhang, C., Huang, L., Zhang, B., Huang, X., You, J., & Jin, C. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2451064 · Cited by 1

The Therapeutic Potential of TGF-β as a Target for Multiple Chronic Diseases: A Comprehensive Review of Pharmacologically Approved Drugs and Investigational Agents

Wal, A., Rasheed, A., Wal, P., Bhise, M. R., Parmar, M., Nathiya, D., Sharma, R. K., & Gasmi, A. (2025) · Current Signal Transduction Therapy · doi:10.2174/0115743624339476250212114656 · Cited by 1

New aspects of TGF-β superfamily signaling in development and disease (2022 FASEB meeting review)

Newfeld, S. J., & O’Connor, M. B. (2022) · Faculty Reviews · doi:10.12703/r/11-36 · Cited by 1

Emerging Anti-cancer Compounds and Immunomodulators for Pancreatic Cancer Treatment

(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4848-6

Design, Synthesis, and In Vitro Antiproliferative Activity of 4,5,6-Trisubstituted 2-Aminopyrimidines as Potential TGF-β Inhibitors

Sachkova, A. A., Rysina, Y. D., Svirshchevskaya, E. V., Grishin, I. D., Fedorov, A. Y., & Shchegravina, E. S. (2024) · Russian Journal of Organic Chemistry · doi:10.1134/s107042802404016x

Tumor microenvironment and metastatic progression of cancer

Hong, E., Park, S., Kim, S., & Ooshima, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824040-3.00006-6

TGFβ1–TNFα-regulated secretion of neutrophil chemokines is independent of epithelial–mesenchymal transition in breast tumor cells

SenGupta, S., Cohen, E., Serrenho, J., Ott, K., Coulombe, P. A., & Parent, C. A. (2025) · Molecular Biology of the Cell · doi:10.1091/mbc.e25-07-0340

La citocina TGF-β y su papel en la comunicación intercelular en el microambiente tumoral: Mecanismos de síntesis, secreción, activación y acción

Meza-Juárez, C. D., Color-Aparicio, V. M., Tecalco-Cruz, Á. C., & Macías‐Silva, M. (2025) · TIP Revista Especializada en Ciencias Químico-Biológicas · doi:10.22201/fesz.23958723e.2025.751

Additional file 1 of The incorporation of acetylated LAP-TGF-β1 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis

Yu, P., Han, Y., Meng, L., Tang, Z., Jin, Z., Zhang, Z., Zhou, Y., Luo, J., Luo, J., Han, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26712095

Additional file 1 of Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment

Lim, Y. W., Coles, G. L., Sandhu, S. K., Johnson, D. S., Adler, A. S., & Stone, E. L. (2021) · Figshare · doi:10.6084/m9.figshare.14670453

Additional file 2 of The incorporation of acetylated LAP-TGF-β1 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis

Yu, P., Han, Y., Meng, L., Tang, Z., Jin, Z., Zhang, Z., Zhou, Y., Luo, J., Luo, J., Han, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26712098

Research progress on the correlation between OPN and immune escape of gastric cancer

Qu, F., Wu, S., & Yu, W. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02075-w

Immune and stromal signaling networks in chordoma: an evidence-weighted review of ligand–receptor interactions and therapeutic implications

Hu, P., Lei, J., Du, S., Zeng, S., Hua, P., Zhou, H., & Wei, F. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03183-0

Inhibition of integrin αvβ8-mediated TGFβ activation and active-TGFβ blockade promote anti-tumor immunity through distinct biological mechanismsPreprint

Williams, K., Mittman, S., Firmino, N. S., Larrick, J. W., Zhang, Z., Whitty, C., Ma, H., Ren, X., Chiu, C., Yang, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.06.735099

Age-stratified mutation patterns in early-onset colorectal cancer reveal distinct molecular features and therapeutic implications

Liu, L., Rose, A. D., Samaddar, A., Ascherman, B. M., Levenson, J., Brown, T. J., Grewal, U. S., & Hornstein, N. J. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100400

Platelet-Tumor Interactions: From Mechanisms Promoting Metastasis to Novel Targeted Therapeutic Strategies

Liu, W., Zhu, Y., Wang, T., Yuan, Y., Yu, X., Zhu, Y., Yin, P., Li, W., & Yuan, Z. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s649895

Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors

Welsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 28

Abstract 4090: Defeating primary checkpoint resistance: SRTβ1-Ab3 is a first-in-class, fully human antibody that renders resistant tumors sensitive to anti-PD-1

Schürpf, T., Martin, C. J., Littlefield, C., Chapron, C., Wawersik, S., Kalra, A. V., Simpson, A., Danehy, F. T., Boston, C., Nikiforov, A., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-4090

TGFβ1-specific antibody spurs anti-tumour immunity

Cully, M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00058-4 · Cited by 2

773 SOF10, selectively blocking latent TGF-β1 activation, potentiates the efficacy of checkpoint blockade therapy by modulating CAF dynamics and T cell infiltration

Sato, I., Kanamori, M., Nakagawa, K., Sun, S., Asanuma, K., Kawauchi, H., Kayukawa, Y., Matsuo, S., Shida-Kawazoe, M., Kashiwagi, D., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-sitc2024.0773 · Cited by 1

First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

Yap, T. A., Barve, M. A., Gainor, J. F., Weekes, C. D., Bockorny, B., Ju, Y., Faucette, R., Bilic, S., Lee-Hoeflich, S. T., Song, G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps3146 · Cited by 7